Clinical Trials Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. May 28, 2018; 24(20): 2191-2202
Published online May 28, 2018. doi: 10.3748/wjg.v24.i20.2191
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Serum CXCL10 levels in occult hepatitis C virus infection patients with different variants of IL-28B rs12979860 (C/C or non-C/C) as compared to chronic hepatitis C virus infection patients. aP < 0.0001; bP = 0.001. OCI: Occult hepatitis C virus infection; CHC: Chronic hepatitis C virus infection.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Comparison of serum CXCL10 levels (A), liver CXCL10 mRNA levels (B), representative (C) and grouped (D) liver CXCL10 IHC scoring, and liver hepatitis C virus RNA levels (E) among IL-28B rs12979860 C/C patients with different CXCL10 rs1439490 polymorphisms. aP < 0.0001; bP = 0.003; cP = 0.009. OCI: Occult hepatitis C virus infection; CHC: Chronic hepatitis C virus infection.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 METAVIR necroinflammation activity (A) and fibrosis stage scores of patients with IL-28B rs12979860 CC genotype (B). aP < 0.0001; bP = 0.04. OCI: Occult hepatitis C virus infection; CHC: Chronic hepatitis C virus infection.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Effect of antiviral therapy on serum CXCL10 levels of IL-28 rs12979860 C/C patients with different CXCL10 G-201A single nucleotide polymorphisms. A: The baseline serum CXCL10 levels of IL-28 rs12979860 C/C patients who completed the Peg-IFNα plus ribavirin treatment; B-C: The serum CXCL10 levels of the patients at the endpoint of antiviral treatment (B) and at 24 wk follow up (C); aP < 0.0001; bP = 0.038; cP = 0.008; dP = 0.008; eP = 0.009. OCI: Occult hepatitis C virus infection; CHC: Chronic hepatitis C virus infection.